Zantac

Zantac Litigation Progresses: Key Developments in Ongoing Legal Battle Over Health Concerns

by

Washington, D.C. — In a colossal legal battle that has captivated national attention, recent months have seen a flurry of lawsuits filed against the manufacturers of the popular heartburn medication Zantac, alleging that it causes cancer. Plaintiffs across the United States claim sustained injury after the drug’s link to cancer became publicly acknowledged, stimulating an avalanche of legal claims. In 2019, the online pharmacy Valisure detected NDMA, a probable human carcinogen, in some batches of Zantac. This finding prompted a deeper look into the drug, which eventually led to its recall by the Food and … Read more

Pharmaceutical Giants Challenge Delaware Court Over Expert Testimony in Zantac Case, Fear Increase in Mass Tort Filings

by

Dover, Delaware — Leading pharmaceutical giants are urging Delaware’s highest court to reconsider a lower court’s decision that greenlit expert testimony in ongoing Zantac litigation, claiming the ruling misaligns with established federal standards. Companies like GlaxoSmithKline, Pfizer, Sanofi, and Boehringer Ingelheim, which are part of the lawsuit focused on the heartburn medication Zantac, fear it could transform Delaware into a hotbed for mass tort litigation. Represented by distinguished law firms including Dechert, Williams & Connolly, DLA Piper, and King & Spalding, these pharmaceutical heavyweights find the Superior Court’s decision unsettling. The ruling by Superior Court … Read more

Zantac State Court Battles Heat Up: Plaintiffs Call for Judge Recusal Amidst Conflict of Interest Concerns

by

Philadelphia — The future of numerous Zantac cancer lawsuits appears uncertain after a pivotal legal blow in which a federal judge dismissed all cases consolidated under the multidistrict litigation (MDL) system, a decision that could potentially sideline thousands of claims unless overturned on appeal. The shockwaves of this decision extend across various state courts, with new filings and ongoing pretrial activities highlighting the resistant pulse of litigation against Zantac’s manufacturers. Zantac, a popular heartburn medication, was pulled from the market in 2020 after it was discovered that the drug could degrade into N-nitrosodimethylamine (NDMA), a … Read more

Philadelphia Zantac Plaintiffs Seek Judge’s Recusal Amid Controversy

by

Philadelphia, PA – In a significant legal development, plaintiffs in the Philadelphia Zantac case are seeking the recusal of the presiding judge over claims of possible bias. This motion arises from concerns voiced by attorneys representing individuals who allege harm from the use of Zantac, a popular heartburn medication. The controversy started when internal communications suggested that the judge might have undisclosed connections to the pharmaceutical industry. These revelations have prompted the plaintiffs’ attorneys to question the impartiality of the judicial process. The legal team argues that ensuring a fair trial is paramount, and any … Read more